TMEM59L promotes neuroendocrine differentiation and enzalutamide resistance in prostate cancer by regulating MUC1/β‐catenin/MYC axis
Xiuchen Guo, Yifan Liu, Jiacheng Huang, Zhiwei Chen, Haihong Liao, Yulin Xu, Xingang Cui, Yongjiang Yu · 2026
Read TMEM59L promotes neuroendocrine differentiation and enzalutamide resistance in prostate cancer by regulating MUC1/β‐catenin/MYC axis by Xiuchen Guo, Yifan Liu, Jiacheng Huang, Zhiwei Chen, Haihong Liao, Yulin Xu, Xingang Cui, Yongjiang Yu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13579383.txt.
Description
Xiuchen Guo and co-authors present a study the catalog lists under 2026. Advanced prostate cancer often resists the hormone drug enzalutamide. Resistance can flip the tumor into a nerve-like, aggressive type. The drivers of that flip were unclear. The team studies a membrane protein called TMEM59L. Data join bulk, single-cell, and spatial gene maps to place the protein in tumors. Resistant cell lines and mouse grafts test its function.
The protein pushes the nerve-like shift and drug resistance. It acts through a chain that joins a surface protein, a signal carrier, and a growth gene. Blocking that chain is a candidate counter-move. Oncologists get a named driver for a feared transition. Treatment-induced type change is a growing problem as hormone drugs improve. A driver with a mapped chain offers drug designers a concrete target list.
Catalog record
| CREATOR | Xiuchen Guo, Yifan Liu, Jiacheng Huang, Zhiwei Chen, Haihong Liao, Yulin Xu, Xingang Cui, Yongjiang Yu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 71 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |